Table 4.

Adjusted odds ratio (aOR) of baseline factors with change to treatment and change to diagnostic investigations

	Change to treatment aOR (95% CI)	Change to investigations aOR (95% CI)
Age (years) <70 versus ≥70	1.34 (1.03–1.74)	0.95 (0.64–1.42)
Gender, female versus male	1.36 (1.07–1.73)	0.90 (0.63–1.29)
Performance status, versus 0
1	0.78 (0.55–1.12)	1.00 (0.57–1.82)
2–3	0.37 (0.25–0.56)	0.72 (0.38–1.39)
Smoking status, versus current smoker
Ex-smoker	0.96 (0.73–1.25)	0.74 (0.50–1.10)
Never smoker	1.51 (0.78–2.86)	0.65 (0.20–1.77)
Histology, versus NSCLC
SCLC	1.27 (0.86–1.89)	0.97 (0.46–1.90)
Radiological diagnosis	0.88 (0.64–1.20)	3.83 (2.44–6.09)
Stage, versus stage I
Stage II	0.95 (0.65–1.38)	1.25 (0.73–2.10)
Stage III	1.56 (1.15–2.13)	1.42 (0.88–2.30)
Region, versus North West England
Yorkshire & North East England	0.62 (0.43–0.90)	0.81 (0.43–1.46)
South East England	0.41 (0.27–0.61)	0.34 (0.13–0.75)
London	0.34 (0.18–0.63)	0.29 (0.05–1.02)
South West England	0.41 (0.23–0.71)	1.62 (0.75–3.36)
Midlands	0.41 (0.26–0.65)	0.64 (0.29–1.31)
Northern Ireland	0.33 (0.20–0.54)	13.87 (8.05–24.47)
Wales	0.62 (0.39–1.01)	2.36 (1.22–4.48)
Scotland	0.09 (0.05–0.14)	0.44 (0.21–0.88)
Ischaemic heart disease, no versus yes	0.94 (0.68–1.28)	1.22 (0.78–1.89)
Congestive heart failure, no versus yes	0.98 (0.54–1.74)	0.54 (0.20–1.27)
Arrhythmia, no versus yes	1.07 (0.71–1.60)	1.04 (0.56–1.86)
Hypertension, no versus yes	0.80 (0.62–1.03)	1.15 (0.79–1.68)
COPD, no versus yes	1.24 (0.96–1.60)	1.29 (0.88–1.88)
Chronic kidney disease, no versus yes	0.78 (0.43–1.36)	2.13 (1.03–4.19)
Diabetes, no versus yes	0.99 (0.71–1.39)	1.08 (0.65–1.75)
Stroke, no versus yes	0.83 (0.52–1.30)	1.03 (0.54–1.87)
Dementia, no versus yes	1.19 (0.39–3.27)	0.91 (0.18–3.36)
Previous malignancy, no versus yes	0.86 (0.64–1.15)	1.12 (0.72–1.70)

CI, confidence interval; COPD, chronic obstructive pulmonary disease; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.